Oncimmune inks Covid-19 biomarker agreement with Cedars-Sinai

Tue, 13th Oct 2020

Immunodiagnostics group Oncimmune said it had signed a commercial agreement with California-based Cedars-Sinai to provide antibody profiling in Covid-19 samples as biomarkers for the disease. Cedars-Sinai was a medical research organisation serving more than 1 million people each year in over 40 locations. It would provide Oncimmune with serum samples from staff exposed to or infected with the SARS-CoV-2 virus. The agreement was signed after Oncimmune announced earlier this month that it had secured UK government funding to develop a Covid-19 biomarker panel. The project with Cedars-Sinai would identify biomarkers of the Covid-19 disease and compare them to a control set of healthy patient samples to be provided by Oncimmune. It would seek to initially profile the antibodies of staff working at Cedars-Sinai hospitals to better understand the effects of the disease in healthcare workers. Story provided by StockMarketWire.com

FTSE 100 Latest
Value6,561.91
Change-92.10